Group 1 - Sangamo Therapeutics reported quarterly earnings of $0.04 per share, exceeding the Zacks Consensus Estimate of a loss of $0.03 per share, and showing a significant improvement from a loss of $0.34 per share a year ago, resulting in an earnings surprise of 233.33% [1] - The company generated revenues of $49.41 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 86.11%, compared to revenues of $9.4 million in the same quarter last year [2] - Sangamo shares have increased approximately 397% since the beginning of the year, significantly outperforming the S&P 500's gain of 25.8% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $13.85 million, and for the current fiscal year, it is -$0.51 on revenues of $27.8 million [7] - The Medical - Biomedical and Genetics industry, to which Sangamo belongs, is currently ranked in the top 29% of over 250 Zacks industries, indicating a favorable outlook for the sector [8] Group 3 - The estimate revisions trend for Sangamo is mixed, leading to a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market in the near future [6] - Another company in the same industry, Mersana Therapeutics, is expected to report a quarterly loss of $0.18 per share, reflecting a year-over-year change of +48.6%, with revenues anticipated to be $9.49 million, up 23.2% from the previous year [9][10]

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has been able to make several great advancements regarding its pipeline in the past year. The most notable program advancement would be regarding the fact that the company caught a huge surprise development from the FDA relating to its Fabry Disease treatment program. That is, it was noted by the U.S. agency that it would be able to file a Biologics License Application [BLA] of isaralgagene civaparvovec for the treatment of patients with Fabry Disease [FD] under an A ...

Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.37 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -6.25%. A quarter ago, it was expected that this drug developer would post a loss of $0.22 per share when it actually produced a loss of $0.27, delivering a surprise of -22.73%. Over the last four quarters, the compa ...

Sangamo Therapeutics (NASDAQ:SGMO) stock is rising higher on Tuesday after the clinical-stage genomic medicine company announced a new license agreement. Sangamo Therapeutics has signed a license agreement Genentech for the development of intravenously administered genomic medicines to treat "certain neurodegenerative diseases." That includes the company's proprietary zinc finger repressors for Alzheimer's disease. This agreement will see Sangamo handle technology transfer and some preclinical activities. G ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communications Sandy Macrae - Chief Executive Officer Amy Pooler - Head of Research Nathalie Dubois-Stringfellow - Chief Development Officer Conference Call Participants James Stamos - Jefferies Gena Wang - Barclays Luis Santos - H.C. Wainwright Ritu Baral - TD Cowen Bill Chappell - Truist Operator Good day, and welcome to the ...

Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to earnings of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -22.73%. A quarter ago, it was expected that this drug developer would post a loss of $0.25 per share when it actually produced a loss of $0.34, delivering a surprise of -36%.Over the last four quarters, the compa ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________ FORM 10-Q ________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 501 Canal Blvd., Richmond, California, 94804 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fr ...

Exhibit 99.1 SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FIRST QUARTER 2024 FINANCIAL RESULTS RICHMOND, California, May 9, 2024 - Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results. "Sangamo continues to progress its neurology-focused genomic medicine pipeline as most recently showcased at the 27 ASGCT Annual Meeting, with foundational advances across our epigenetic regulation programs and capsid ...

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced preclinical data from its proprietary adeno-associated virus (AAV) capsid variant, STAC-BBB, that demonstrated robust penetration of the blood-brain barrier (BBB) and strong transgene expression throughout the central nervous system (CNS) of NHPs when administered intravenously at clinically-relevant doses, outperforming results obtained by Sangamo for other known neurotropic capsid vari ...

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its fourth quarter and full year 2023 financial results before the market opens on Wednesday, March 13, 2024. The Company will hold a conference call at 4:30 p.m. Eastern on Wednesday, March 13, which will be open to the public. During the conference call, the company will review its financial results and provide business updates. Participa ...